Identification of a peroxisome proliferator responsive element (PPRE)-like cis-element in mouse plasminogen activator inhibitor-1 gene promoter

Biochemical and Biophysical Research Communications

Volumn 347, Issue 3, 2006, Pages 821-826

  Chen, Jie Gen ^a   Li, Xi ^a,b   Huang, Hai Yan ^a,b   Liu, Hong Lei ^b   Liu, De Guo ^a   Song, Tan Jing ^a   Ma, Chun Gu ^a   Ma, Duan ^a,b   Song, Hou Yan ^a   Tang, Qi Qun ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

3T3 L1; Peroxisome proliferator responsive element; Peroxisome proliferator activated receptor ; Pioglitazone; Plasminogen activator inhibitor 1

Indexed keywords

PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE; PROMOTER REGION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; LIGANDS; MICE; PEROXISOME PROLIFERATORS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC;

EID: 33746215048     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.170     Document Type: Article

References (41)

1. Loskutoff D.J., and Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1-6
2. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 1357-1364
3. Wiman B., and Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb. Hemost. 16 (1990) 207-216
4. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., and Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
5. Juhan-Vague I., Alessi M.C., and Vague P. Increased plasma plasminogen activator inhibitor 1 levels. Diabetologia 34 (1991) 457-462
6. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342 (2000) 1792-1801
7. De Taeye B., Smith L.H., and Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr. Opin. Pharmacol. 5 (2005) 149-154
8. Hou B., Eren M., Painter C.A., Covington J.W., Dixon J.D., Schoenhard J.A., and Vaughan D.E. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J. Biol. Chem. 279 (2004) 18127-18136
9. Gruber F., Hufnagl P., Hofer-Warbinek R., Schmid J.A., Breuss J.M., Huber-Beckmann R., Lucerna M., Papac N., Harant H., Lindley I., de Martin R., and Binder B.R. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood 101 (2003) 3042-3048
10. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17 (1998) 3091-3100
11. Fink T., Kazlauskas A., Poellinger L., Ebbesen P., and Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99 (2002) 2077-2083
12. Smith L.H., Coats S.R., Qin H., Petrie M.S., Covington J.W., Su M., Eren M., and Vaughan D.E. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circ. Res. 95 (2004) 269-275
13. Eriksson P., Nilsson L., Karpe F., and Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 20-26
14. Chen Y.Q., Su M., Walia R.R., Hao Q., Covington J.W., and Vaughan D.E. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J. Biol. Chem. 273 (1998) 8225-8231
15. Juge-Aubry C., Pernin A., Favez T., Burger A.G., Wahli W., Meier C.A., and Desvergne B. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. J. Biol. Chem. 272 (1997) 25252-25259
16. Fajas L., Fruchart J.C., and Auwerx J. Transcriptional control of adipogenesis. Curr. Opin. Cell Biol. 10 (1998) 165-173
17. Lowell B.B. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
18. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., and Mortensen R.M. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 (1999) 611-617
19. Samad F., Yamamoto K., and Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J. Clin. Invest. 97 (1996) 37-46
20. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 546-551
21. Ihara H., Urano T., Takada A., and Loskutoff D.J. Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB J. 15 (2001) 1233-1235
22. Prendergast G.C., and Diamond L.E. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol. Cell Biol. 10 (1990) 1265-1269
23. Tang Q.Q., and Lane M.D. Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes Dev. 13 (1999) 2231-2241
24. Schachtrup C., Emmler T., Bleck B., Sandqvist A., and Spener F. Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem. J. 382 Pt1 (2004) 239-245
25. Juhan-Vague I., Alessi M.C., and Morange P.E. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann. Med. 32 Suppl. 1 (2000) 78-84
26. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
27. Mavri A., Alessi M.C., Bastelica D., Geel-Georgelin O., Fina F., Sentocnik J.T., Stegnar M., and Juhan-Vague I. Subcutaneous abdominal but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 44 (2001) 2025-2031
28. Mertens I., Van der Planken M., Corthouts B., Wauters M., Peiffer F., De Leeuw I., and Van Gaal L. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm. Metab. Res. 33 (2001) 602-607
29. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., and Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 41 (1998) 65-71
30. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., Brown N.J., Swift L.L., McGuinness O.P., Wasserman D.H., Vaughan D.E., and Fogo A.B. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
31. MacDougald O.A., and Lane M.D. Transcriptional regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64 (1995) 345-373
32. Cornelius P., MacDougald O.A., and Lane M.D. Regulation of adipocyte development. Annu. Rev. Nutr. 14 (1994) 99-129
33. Mandrup S., and Lane M.D. Regulating adipogenesis. J. Biol. Chem. 272 (1997) 5367-5370
34. Rosen E.D., and Spiegelman B.M. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16 (2000) 145-171
35. Seo J.B., Noh M.J., Yoo E.J., Park S.Y., Park J., Lee I.K., Park S.D., and Kim J.B. Functional characterization of the human resistin promoter with adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element binding protein 1c and CCAAT enhancer binding protein-alpha. Mol. Endocrinol. 17 (2003) 1522-1533
36. Seo J.B., Moon H.M., Noh M.J., Lee Y.S., Jeong H.W., Yoo E.J., Kim W.S., Park J., Youn B.S., Kim J.W., Park S.D., and Kim J.B. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J. Biol. Chem. 279 (2004) 22108-22117
37. MacDougald O.A., and Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol. Metab. 13 (2002) 5-11
38. Bosma P.J., van den Berg E.A., Kooistra T., Siemieniak D.R., and Slightom J.L. Human plasminogen activator inhibitor-1 gene. J. Biol. Chem. 263 (1988) 9129-9141
39. Bar-Tana J. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. Toxicol. Lett. 120 (2001) 9-19
40. Gottschling-Zeller H., Rohrig K., and Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia 43 (2000) 377-383
41. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., and Spiegelman B.M. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 275 (2000) 18527-18533